桥本甲状腺炎多重耐药与外排转运体高表达一例
本文报告一例桥本甲状腺炎患者对多种口服药物耐药,外周血白细胞ABCG2/BCRP表达显著高于健康志愿者,淋巴细胞外排柔红霉素能力可被ABCG2/BCRP抑制剂fumitremorgin C抑制。完整左甲状腺素片使TSH升高248.6%,压碎后降低45.1%;完整氯沙坦片改为压碎后平均血压从166.3/108.5 mmHg降至125.9/78.8 mmHg。提示ABCG2/BCRP高表达和外排转运体活性增强可能参与口服完整片剂无效,压碎片剂对部分患者可能更有效。
要点
- 桥本甲状腺炎患者可因ABCG2/BCRP高表达出现口服药物多重耐药。
- 该患者完整左甲状腺素片使TSH升高248.6%,压碎后降低45.1%。
- 压碎片剂可能改善部分治疗抵抗患者的口服药物疗效。
核心结论
- ABCG2/BCRP高表达及外排转运体活性增强可能参与治疗抵抗性桥本甲状腺炎患者口服完整片剂无效。
- 压碎片剂对部分治疗抵抗的桥本甲状腺炎患者可能更有效。
研究设计与样本
- 病例报告,报告一例桥本甲状腺炎、免疫性血小板减少症和难治性高血压患者。
- 采用外周血白细胞基因表达谱分析,并与健康志愿者比较ABCG2/BCRP表达。
- 检测患者淋巴细胞柔红霉素外排能力及fumitremorgin C的抑制效果。
主要发现
- 患者外周血白细胞ABCG2/BCRP表达显著高于健康志愿者。
- 患者淋巴细胞柔红霉素外排能力增强,可被特异性ABCG2/BCRP抑制剂fumitremorgin C抑制。
- 完整左甲状腺素片给药后TSH升高248.6%,压碎片剂后TSH降低45.1%。
- 完整氯沙坦片改为压碎片剂后,平均血压从166.3/108.5 mmHg降至125.9/78.8 mmHg。
临床怎么用
- 对口服左甲状腺素等药物反应不佳的桥本甲状腺炎患者,可考虑评估ABCG2/BCRP相关外排转运体机制。
- 部分治疗抵抗患者改用压碎片剂可能改善口服药物疗效,但需结合具体药物和临床情况判断。
局限性
- 本文为单例病例报告,结论需在更大样本中验证。
- ABCG2/BCRP高表达与口服完整片剂无效的因果关系尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hashimoto's thyroiditis is the most common cause of hypothyroidism. Patients usually respond well to oral synthetic thyroxine (levothyroxine); however, for unknown reasons some individuals present with treatment-resistant Hashimoto thyroiditis. In cases of cancer and certain infectious diseases, the ATP binding cassette (ABC) transporters have been implicated in multidrug resistance, and we hypothesized and investigated a role of ABC transporters in drug-resistant Hashimoto's thyroiditis. CASE DESCRIPTION: The patient whose case we report had a history of Hashimoto's thyroiditis, immune thrombocytopenia, and refractory hypertension, with varying treatment resistance to the oral medications prescribed for each condition. In order to establish or exclude a genetic basis for her illness, we examined the patient's gene expression profiles using peripheral blood leukocytes, and found that ABCG2/BCRPexpression was significantly high compared with healthy volunteers. Also, the increased daunomycin efflux capacity of our patient's lymphocytes was successfully inhibited by fumitremorgin C, a specific ABCG2/BCRP inhibitor, and the patient's level of thyroid-stimulating hormone increased by 248.6% after administration of intact levothyroxine tablets but decreased by 45.1% when tablets were crushed. Her average blood pressure decreased from 166.3/108.5 mmHg to 125.9/78.8 mmHg when switching from intact to crushed losartan tablets. CONCLUSIONS: High expression and accelerated efflux transporter activity of ABCG2/BCRP in the small intestine are expected to contribute to the ineffectiveness of orally administered intact tablets in cases with treatment-resistant Hashimoto's thyroiditis, and crushed tablets can be more effective for some of these patients.
引用
- Yoshida T, Nakayama A, Tamura A, et al. A Case of Hashimoto's Thyroiditis with Multiple Drug Resistance and High Expression of Efflux Transporters. J Clin Endocrinol Metab. 2020. PMID: 31614366. doi:10.1210/clinem/dgz073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。